TY - JOUR
T1 - Radical hysterectomy in early cervical cancer in Europe
T2 - Characteristics, outcomes and evaluation of ESGO quality indicators
AU - Boria, Felix
AU - Chiva, Luis
AU - Zanagnolo, Vanna
AU - Querleu, Denis
AU - Martin-Calvo, Nerea
AU - Capîlna, Mihai Emil
AU - Fagotti, Anna
AU - Kucukmetin, Ali
AU - Mom, Constantijne
AU - Chakalova,, Galina
AU - Shamistan, Aliyev
AU - Malzoni, Mario
AU - Narducci, Fabrice
AU - Arencibia, Octavio
AU - Raspagliesi, Francesco
AU - Toptas, Tayfun
AU - Cibula, David
AU - Kaidarova, Dilyara
AU - Meydanli, Mehmet Mutlu
AU - Tavares, Mariana
AU - Golub, Dmytro
AU - Perrone, Anna Myriam
AU - Poka, Robert
AU - Tsolakidis, Dimitrios
AU - Vujić, Goran
AU - Jedryka, Marcin A.
AU - Zusterzeel, Petra L.M.
AU - Beltman, Jogchum Jan
AU - Goffin, Frederic
AU - Haidopoulos, Dimitrios
AU - Haller, Herman
AU - Jach, Robert
AU - Yezhova, Iryna
AU - Berlev, Igor
AU - Bernardino, Margarida
AU - Bharathan, Rasiah
AU - Lanner, Maximilian
AU - Mäenpaa, Minna M.
AU - Sukhin, Vladyslav
AU - Feron, Jean Guillaume
AU - Fruscio, Robert
AU - Kukk, Kersti
AU - Ponce, Jordi
AU - Alonso-Espías, María
AU - Minguez, Jose Angel
AU - Vázquez-Vicente, Daniel
AU - Manzour, Nabil
AU - Jurado, Matias
AU - Castellanos, Teresa
AU - Chacon, Enrique
AU - Alcazar, Juan Luis
N1 - Publisher Copyright:
© IGCS and ESGO 2021. No commercial re-use. See rights and permissions. Published by BMJ.
PY - 2021/9
Y1 - 2021/9
N2 - Introduction: Comprehensive updated information on cervical cancer surgical treatment in Europe is scarce. Objective: To evaluate baseline characteristics of women with early cervical cancer and to analyze the outcomes of the ESGO quality indicators after radical hysterectomy in the SUCCOR database. Methods: The SUCCOR database consisted of 1272 patients who underwent radical hysterectomy for stage IB1 cervical cancer (FIGO 2009) between January 2013 and December 2014. After exclusion criteria, the final sample included 1156 patients. This study first described the clinical, surgical, pathological, and follow-up variables of this population and then analyzed the outcomes (disease-free survival and overall survival) after radical hysterectomy. Surgical-related ESGO quality indicators were assessed and the accomplishment of the stated recommendations was verified. Results: The mean age of the patients was 47.1 years (SD 10.8), with a mean body mass index of 25.4 kg/m2 (SD 4.9). A total of 423 (36.6%) patients had a previous cone biopsy. Tumor size (clinical examination) <2 cm was observed in 667 (57.7%) patients. The most frequent histology type was squamous carcinoma (794 (68.7%) patients), and positive lymph nodes were found in 143 (12.4%) patients. A total of 633 (54.8%) patients were operated by open abdominal surgery. Intra-operative complications occurred in 108 (9.3%) patients, and post-operative complications during the first month occurred in 249 (21.5%) patients, with bladder dysfunction as the most frequent event (119 (10.3%) patients). Clavien-Dindo grade III or higher complication occurred in 56 (4.8%) patients. A total of 510 (44.1%) patients received adjuvant therapy. After a median follow-up of 58 months (range 0-84), the 5-year disease-free survival was 88.3%, and the overall survival was 94.9%. In our population, 10 of the 11 surgical-related quality indicators currently recommended by ESGO were fully fulfilled 5 years before its implementation. Conclusions: In this European cohort, the rate of adjuvant therapy after radical hysterectomy is higher than for most similar patients reported in the literature. The majority of centers were already following the European recommendations even 5 years prior to the ESGO quality indicator implementations.
AB - Introduction: Comprehensive updated information on cervical cancer surgical treatment in Europe is scarce. Objective: To evaluate baseline characteristics of women with early cervical cancer and to analyze the outcomes of the ESGO quality indicators after radical hysterectomy in the SUCCOR database. Methods: The SUCCOR database consisted of 1272 patients who underwent radical hysterectomy for stage IB1 cervical cancer (FIGO 2009) between January 2013 and December 2014. After exclusion criteria, the final sample included 1156 patients. This study first described the clinical, surgical, pathological, and follow-up variables of this population and then analyzed the outcomes (disease-free survival and overall survival) after radical hysterectomy. Surgical-related ESGO quality indicators were assessed and the accomplishment of the stated recommendations was verified. Results: The mean age of the patients was 47.1 years (SD 10.8), with a mean body mass index of 25.4 kg/m2 (SD 4.9). A total of 423 (36.6%) patients had a previous cone biopsy. Tumor size (clinical examination) <2 cm was observed in 667 (57.7%) patients. The most frequent histology type was squamous carcinoma (794 (68.7%) patients), and positive lymph nodes were found in 143 (12.4%) patients. A total of 633 (54.8%) patients were operated by open abdominal surgery. Intra-operative complications occurred in 108 (9.3%) patients, and post-operative complications during the first month occurred in 249 (21.5%) patients, with bladder dysfunction as the most frequent event (119 (10.3%) patients). Clavien-Dindo grade III or higher complication occurred in 56 (4.8%) patients. A total of 510 (44.1%) patients received adjuvant therapy. After a median follow-up of 58 months (range 0-84), the 5-year disease-free survival was 88.3%, and the overall survival was 94.9%. In our population, 10 of the 11 surgical-related quality indicators currently recommended by ESGO were fully fulfilled 5 years before its implementation. Conclusions: In this European cohort, the rate of adjuvant therapy after radical hysterectomy is higher than for most similar patients reported in the literature. The majority of centers were already following the European recommendations even 5 years prior to the ESGO quality indicator implementations.
KW - cervical cancer
KW - hysterectomy
KW - postoperative complications
KW - radiation
KW - SLN and lympadenectomy
U2 - 10.1136/ijgc-2021-002587
DO - 10.1136/ijgc-2021-002587
M3 - Article
AN - SCOPUS:85111428259
SN - 1048-891X
VL - 31
SP - 1212
EP - 1219
JO - International Journal of Gynecological Cancer
JF - International Journal of Gynecological Cancer
IS - 9
ER -